Target intelligence / Profile preview

RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72)

Target
SSU72
Molecular classification
Enzyme, Protein phosphatase (Ser/Thr-specific), Member of the cleavage/polyadenylation factor (CPF) complex
01

Overview

SSU72 is an enzyme that specifically dephosphorylates serine-5 and serine-7 residues in the C-terminal domain (CTD) of RNA polymerase II, playing a critical role in regulating the transcription cycle from initiation to termination[1][3]. As a component of the cleavage/polyadenylation factor (CPF) complex, SSU72 is required for proper mRNA processing and transcription termination[1][3]. Its activity is tightly coordinated with other kinases and phosphatases during gene expression, and it is required for assembly and stabilization of the preinitiation complex (PIC)[2][3]. SSU72 is also essential for reinitiating transcription by “resetting” RNA polymerase II through CTD dephosphorylation. It exhibits additional functions outside transcription, including telomere maintenance, chromatid cohesion, and phosphate homeostasis, especially in yeast[3]. No interacting therapeutic drugs are currently known; however, inhibition or dysregulation of SSU72 would likely have profound biological effects due to the enzyme’s central role in transcription and genome stability[1][2][3].

Other names
SSU72HSPC182PNAS-120CTD phosphatase SSU72
02

Mechanism of action

Drugs (if available) would inhibit or modulate the phosphatase activity of SSU72, affecting CTD phosphorylation and thus transcription initiation, elongation, or termination[1][2][3].

03

Biological functions

Transcription regulation (CTD phosphatase activity)mRNA 3’ end processing (cleavage and polyadenylation)Transcription terminationAssembly of the preinitiation complex (PIC)Maintenance of gene looping (promoter-terminator crosstalk)Telomere maintenanceChromatid cohesion and condensation (in higher eukaryotes)Regulation of phosphate homeostasis (fission yeast)
04

Disease associations

Cancer (noted in transcriptional regulation, though no specific mutation or role as a driver reported)Other (roles in genomic stability, possibly implicated indirectly in diseases associated with faulty transcription termination or chromatid cohesion)
05

Safety considerations

Targeting SSU72 could disrupt fundamental gene expression and mRNA processing, posing risks of widespread transcriptional dysfunction, impaired cell proliferation, or cell death[1][2][3].As a central regulator of transcription, on/off-target effects and systemic toxicity would be major challenges.

Beyond the preview

Go deeper on RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (SSU72).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call